Report Detail

Pharma & Healthcare Axillary Hyperhidrosis - Pipeline Review, H2 2019

  • RnM3839145
  • |
  • 28 November, 2019
  • |
  • Global
  • |
  • 47 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Axillary Hyperhidrosis - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2019, provides an overview of the Axillary Hyperhidrosis (Dermatology) pipeline landscape.

Axillary hyperhidrosis also referred to as excessive underarm sweating. Excessive sweating in the affected area is caused by over activity of the nerves linked to the sweat glands. Specifically, acetylcholine, a chemical in the body that transmits nerve signals, is released from nerve endings and stimulates secretion of sweat. The condition most frequently develops in adolescence or young adulthood. Treatment includes anticholinergic drugs, surgery and antiperspirants.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Axillary Hyperhidrosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Axillary Hyperhidrosis (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Axillary Hyperhidrosis (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Axillary Hyperhidrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 4, 1, 1 and 2 respectively.

Axillary Hyperhidrosis (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Axillary Hyperhidrosis (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Axillary Hyperhidrosis (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Axillary Hyperhidrosis (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Axillary Hyperhidrosis (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Axillary Hyperhidrosis (Dermatology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Axillary Hyperhidrosis (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Axillary Hyperhidrosis (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Axillary Hyperhidrosis - Overview

              Axillary Hyperhidrosis - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Axillary Hyperhidrosis - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Axillary Hyperhidrosis - Companies Involved in Therapeutics Development

                                  Brickell Biotech Inc

                                    DelNova Inc

                                      Dermata Therapeutics LLC

                                        Dermavant Sciences Inc

                                          Dermira Inc

                                            Dr. August Wolff GmbH & Co KG Arzneimittel

                                              Medytox Inc

                                                Revance Therapeutics Inc

                                                  Axillary Hyperhidrosis - Drug Profiles

                                                    (oxybutynin + pilocarpine) - Drug Profile

                                                      Product Description

                                                        Mechanism Of Action

                                                          R&D Progress

                                                            DMT-410 - Drug Profile

                                                              Product Description

                                                                Mechanism Of Action

                                                                  R&D Progress

                                                                    glycopyrrolate - Drug Profile

                                                                      Product Description

                                                                        Mechanism Of Action

                                                                          R&D Progress

                                                                            glycopyrronium tosylate - Drug Profile

                                                                              Product Description

                                                                                Mechanism Of Action

                                                                                  R&D Progress

                                                                                    nivobotulinumtoxin A - Drug Profile

                                                                                      Product Description

                                                                                        Mechanism Of Action

                                                                                          R&D Progress

                                                                                            onabotulinumtoxinA biosimilar - Drug Profile

                                                                                              Product Description

                                                                                                Mechanism Of Action

                                                                                                  R&D Progress

                                                                                                    ReViVox - Drug Profile

                                                                                                      Product Description

                                                                                                        Mechanism Of Action

                                                                                                          R&D Progress

                                                                                                            sofpironium bromide - Drug Profile

                                                                                                              Product Description

                                                                                                                Mechanism Of Action

                                                                                                                  R&D Progress

                                                                                                                    Axillary Hyperhidrosis - Dormant Projects

                                                                                                                      Axillary Hyperhidrosis - Discontinued Products

                                                                                                                        Axillary Hyperhidrosis - Product Development Milestones

                                                                                                                          Featured News & Press Releases

                                                                                                                            Jul 09, 2019: Dermata Therapeutics announces positive results from a phase 1 clinical trial of DMT410, a new topical delivery mechanism for botulinum toxin

                                                                                                                              Feb 20, 2018: Sofpironium Bromide Demonstrates Promising Potential as a Safe and Effective First-Line Treatment for Primary Axillary Hyperhidrosis (Excessive Underarm Sweating)

                                                                                                                                Oct 24, 2017: Brickell Biotech Announces Positive Phase 2b Study Results for BBI-4000 (Sofpironium Bromide) in Subjects with Primary Axillary Hyperhidrosis

                                                                                                                                  Feb 27, 2017: TheraVida Announces Publication of Phase 2 Results for THVD-102 in Hyperhidrosis

                                                                                                                                    Oct 03, 2016: THVD-102 Demonstrates Promising Potential as an Orally Administered Treatment for Hyperhidrosis

                                                                                                                                      Mar 07, 2016: BBI-4000 (Sofpironium Bromide) Demonstrates Promising Potential as a Safe and Effective First-line Treatment for Excessive Underarm Sweating

                                                                                                                                        Dec 17, 2015: Brickell Biotech Achieves Statistically Significant and Clinically Meaningful Phase 2b Results for BBI-4000 in Patients with Hyperhidrosis

                                                                                                                                          Sep 24, 2014: Brickell Biotech Announces Positive Preliminary Results of a Pilot Clinical Study of BBI-4000 for the Treatment of Hyperhidrosis

                                                                                                                                            Appendix

                                                                                                                                              Methodology

                                                                                                                                                Coverage

                                                                                                                                                  Secondary Research

                                                                                                                                                    Primary Research

                                                                                                                                                      Expert Panel Validation

                                                                                                                                                        Contact Us

                                                                                                                                                          Disclaimer

                                                                                                                                                          Summary:
                                                                                                                                                          Get latest Market Research Reports on Axillary Hyperhidrosis. Industry analysis & Market Report on Axillary Hyperhidrosis is a syndicated market report, published as Axillary Hyperhidrosis - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Axillary Hyperhidrosis market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                          Last updated on

                                                                                                                                                          REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                          Purchase this Report

                                                                                                                                                          $2,000.00
                                                                                                                                                          $4,000.00
                                                                                                                                                          $6,000.00
                                                                                                                                                          1,590.00
                                                                                                                                                          3,180.00
                                                                                                                                                          4,770.00
                                                                                                                                                          1,850.00
                                                                                                                                                          3,700.00
                                                                                                                                                          5,550.00
                                                                                                                                                          312,840.00
                                                                                                                                                          625,680.00
                                                                                                                                                          938,520.00
                                                                                                                                                          167,060.00
                                                                                                                                                          334,120.00
                                                                                                                                                          501,180.00
                                                                                                                                                          Credit card Logo

                                                                                                                                                          Related Reports


                                                                                                                                                          Reason to Buy

                                                                                                                                                          Request for Sample of this report